Current understanding of HIV-1 and T-cell adaptive immunity: Progress to date

Microbial Pathogenesis

Volumn 73, Issue 1, 2014, Pages 60-69

  Mohan, Teena ^a   Bhatnagar, Santwana ^a   Gupta, Dablu L ^a   Rao, D N ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Differentiation; Immune activation; Immune exhaustion; Proliferation

Indexed keywords

CD38 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIGEN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 9; KI 67 ANTIGEN; KIDNEY INJURY MOLECULE 1; LYMPHOCYTE ANTIGEN RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PERFORIN; PROGRAMMED DEATH 1 RECEPTOR; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN CONTAINING MOLECULE 3; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; APOPTOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL LOSS; CELL MATURATION; CELLULAR IMMUNITY; CLONE; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; GENE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE EXHAUSTION; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; IMMUNOSENESCENCE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE ACTIVATION GENE 3; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MONOCYTE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SENESCENCE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; TISSUE SPECIFICITY; UPREGULATION; VIRUS REPLICATION; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE EVASION; IMMUNOLOGY;

ADAPTIVE IMMUNITY; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNE EVASION; T-LYMPHOCYTES;

EID: 84925884911     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2014.06.003     Document Type: Review

References (138)

1. Barre-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220:868-871.
2. Siliciano J.D., Siliciano R.F. Latency and viral persistence in HIV-1 infection. JClin Invest 2000, 106:823-825.
3. + T-cells in lymphoid tissues during simian immunodeficiency virus infection. JVirol 2000, 74:11001-11007.
4. + T-cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection. JInfect Dis 2003, 187:769-776.
5. + T-cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. JExp Med 2004, 200:749-759.
6. + T-cell depletion and viral replication in SIV infection. Science 1998, 280:427-431.
7. + T-cell depletion in primary simian immunodeficiency virus infection. JVirol 1998, 72:6421-6429.
8. Lane H.C., Masur H., Edgar L.C., Whalen G., Rook A.H., Fauci A.S. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. NEngl J Med 1983, 309(8):453-458.
9. Hellerstein M., Hanley M.B., Cesar D., Siler S., Papageorgopoulos C., Wieder E., et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1- infected humans. Nat Med 1999, 5(1):83-89.
10. Hazenberg M.D., Stuart J.W., Otto S.A., Borlefs J.C., deBoer R.J., Miedema F., et al. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000, 95(1):249-255.
11. Valdez H., Lederman M.M. Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev 1997, 187-228.
12. Sailaja G., Skountzou I., Quan F.S., Compans R.W., Kanq S.M. Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology 2007, 362(2):331-341.
13. Ascher M.S., Sheppard H.W. Aunified hypothesis for three cardinal features of HIV immunology. JAcquir Immune Defic Syndr 1991, 4:97-98.
14. + T-cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 2005, 102:13974-13979.
15. Schindler M., Munch J., Kutsch O., Li H., Santiago M.L., Bibollet-Ruche, et al. Nef-mediated suppression of T-cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2006, 125:1055-1067.
16. Fonteneau J.F., Larsson M., Beignon A.S., McKenna K., Dasilva I., Amara A., et al. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. JVirol 2004, 78:5223-5232.
17. Beignon A.S., McKenna K., Skoberne M., Manches O., DaSilva I., Kavangh D.G., et al. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. JClin Invest 2005, 115:3265-3275.
18. Brenchley J.M., Price D.A., Douek D.C. HIV disease: fallout from a mucosal catastrophe?. Nat Immunol 2006, 7:235-239.
19. Brenchley J.M., Price D.A., Schacker T.W., Assher T.E., Silvestri G., Rao S., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
20. Bafica A., Scanga C.A., Schito M., Chaussabel D., Sher A. Influence of coinfecting pathogens on HIV expression: evidence for a role of Toll-like receptors. JImmunol 2004, 172:7229-7234.
21. Borkow G., Bentwich Z. HIV and helminth co-infection: is deworming necessary?. Parasite Immunol 2006, 28:605-612.
22. Estaquier J., Idziorek T., de Bels F., Barre-Sinoussi F., Hurtel B., Aubertin A.M., et al. Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections. Proc Natl Acad Sci U S A 1994, 91:9431-9435.
23. Finkel T.H., Tudor-Williams G., Banda N.K., Cotton M.F., Curiel T., Monks C., et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1995, 1:129-134.
24. Katsikis P.D., Wunderlich E.S., Smith C.A., Herzenberg L.A., Herzenberg L.A. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. JExp Med 1995, 181:2029-2036.
25. Muro-Cacho C.A., Pantaleo G., Fauci A.S. Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. JImmunol 1995, 154:5555-5566.
26. Gougeon M.L., Lecoeur H., Dulioust A., Enou M.G., Crouvoiser M., Goujard C., et al. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T-cells correlates with lymphocyte activation and with disease progression. JImmunol 1996, 156:3509-3520.
27. + regulatory T-cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. JVirol 2004, 78:2454-2459.
28. Andersson J., Boasso A., Nilsson J., Zhang R., Shire N.J., Lindback S., et al. The prevalence of regulatory T-cells in lymphoid tissue is correlated with viral load in HIV-infected patients. JImmunol 2005, 174:3143-3147.
29. Baker C.A., Clark R., Ventura F., Jones N.G., Guzman D., Bangsberg D.R., et al. Peripheral CD4 loss of regulatory T-cells is associated with persistent viraemia in chronic HIV infection. Clin Exp Immunol 2007, 147:533-539.
30. Eggena M.P., Barugahare B., Jones N., Okello M., Mutalya S., Kityo C., et al. Depletion of regulatory T-cells in HIV infection is associated with immune activation. JImmunol 2005, 174:4407-4414.
31. + regulatory T-cells are highly increased in untreated HIV infection and normalize after suppressive HAART. Blood 2006, 108:3072-3078.
32. +) HIV-specific T-cell immune responses invitro and are associated with favorable clinical markers of disease status. JExp Med 2004, 200:331-343.
33. + regulatory T-cells from HIV-infected individuals. Proc Natl Acad Sci U S A 2007, 104:3390-3395.
34. Legrand F.A., Nixon D.F., Loo C.P., Ono E., Chapman J.M., Miyamoto M., et al. Strong HIV-1-specific T-cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T-cell removal. PLoS ONE 2006, 1:e102.
35. + regulatory T-cells in antiretroviral-naïve HIV patients. AIDS 2006, 20:1669-1671.
36. Nilsson J., Boasso A., Velilla P.A., Zhang R., Vaccari M., Ranchini G., et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood 2006, 108:3808-3817.
37. + regulatory T-cells in HIV infection. Microbes Infect 2005, 7:1063-1065.
38. Oswald-Richter K., Grill S.M., Shariat N., Leelawong M., Sundrud M.S., Haas D.W., et al. HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol 2004, 2:E198.
39. + regulatory T-cells to immune status in HIV-infected patients. AIDS 2005, 19:879-886.
40. + regulatory T-cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 2004, 104:3249-3256.
41. McDougal J.S., Mawle A., Cort S.P., Nicholson J.K., Cross G.D., Scheppler-Campbell J.A., et al. Cellular tropism of the human retrovirus HTLV-III/LAV. I. Role of T-cell activation and expression of the T4 antigen. JImmunol 1985, 135:3151-3162.
42. Folks T., Kelly J., Benn S., Kinter A., Justement J., Gold J., et al. Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. JImmunol 1985, 136:4049-4053.
43. + T-cells creates new targets for HIV-1 infection in human lymphoid tissue exvivo. Blood 2008, 111:699-704.
44. + T-cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. JAcquir Immune Defic Syndr 1993, 6:904-912.
45. + T-cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. JAcquir Immune Defic Syndr Hum Retrovirol 1997, 16:83-92.
46. + T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. JAcquir Immune Defic Syndr Hum Retrovirol 1998, 18:332-340.
47. Ganesan A., Chattopadhyay P.K., Brodie T.M. Immunologic and virologic events in early HIV infection predict subsequent rate of progression. JInfect Dis 2010, 201:272-284. Group IDCRPHIVW.
48. + T-cell activation is associated with low susceptibility to HIV-1 infection. JImmunol 2005, 175:6117-6122.
49. van Asten L., Danisman F., Otto S.A., Borghans J.A.M., Hazenberg M.D., Coutinho R.A., et al. Pre-seroconversion immune status predicts the rate of CD4 T-cell decline following HIV infection. AIDS 2004, 18:1885-1893.
50. Anthony K.B., Yoder C., Metcalf J.A., DerSimonian R., Orenstein J.M., Stevens R.A., et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T-cell activation and turnover. JAcquir Immune Defic Syndr 2003, 33:125-133.
51. Giorgi J.V., Detels R. T-cell subsetalterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin Immunol Immunopathol 1989, 52:10-18.
52. + cell levels. The Multicenter AIDS Cohort Study Group. JInfect Dis 1994, 170:775-781.
53. Dyrhol-Riise A.M., Voltersvik P., Olofsson J., Asjo B. Activation of CD8 T-cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection. AIDS 1999, 13:2365-2376.
54. + lymphocytes. Role of the human CD38 molecule. JImmunol 1994, 153:952-959.
55. + T-cell activation in HIV-1 infected Ugandans. Plos One Apr 19 2011, 6(4):e18779.
56. Testi R., D'Ambrosio D., De Maria R., Santoni A. The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol Today 1994, 15:479-483.
57. Brenchley J.M., Douek D.C. Flow cytometric analysis of human antigen-specific T-cell proliferation. Methods Cell Biol 2004, 75:481-496.
58. + T-cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. JInfect Dis 1998, 178:1279-1287.
59. Hellerstein M.K. Measurement of T-cell kinetics: recent methodologic advances. Immunol Today 1999, 20:438-441.
60. + T-cells in HIV infection. Plos Comput Biol May 22, 2014, 10(5):e1003630.
61. Grossman Z., Meier-Schellersheim M., Paul W.E., Picker L.J. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 2006, 12:289-295.
62. + T-cell depletion in HIV infection: are we closer to understanding the cause?. Nat Med 2002, 8:319-323.
63. Appay V., Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. JPathol 2008, 214:231-241.
64. Phillips A.N. Reduction of HIV concentration during acute infection: independence from a specific immune response. Science 1996, 271:497-499.
65. Centlivre M., Sala M., Wain-Hobson S., Berkhout B. In HIV-1 pathogenesis the die is cast during primary infection. AIDS 2007, 21:1-11.
66. Naniche D., Letang E., Nhampossa T., David C., Menendez C., Alonso P. Alterations in T-cell subsets in human immunodeficiency virus-Infected adults with co-infections in Southern Mozambique. Am J Trop Med Hyg 2011, 85(4):776-778.
67. Roederer JG, Dubs MT, Anderson PA, Raju PA, Herzenberg LA, Herzenberg LA. CD8 naïve T-cell counts decrease progressively in HIV-infected adults, J Clin Invest 95:2061-206.
68. Chattopadhyay P.K., Douek D.C., Gange S.J., Chadwick K.R., Hellerstein M., Margolick J.B. Longitudinal assessment of de novo T-cell production in relation to HIV-associated T-cell homeostasis failure. AIDS Res Hum Retrovir 1995, 22:501-507.
69. Chattopadhyay P.K., Roederer M. Immunophenotyping of T-cell subpopulations in HIV disease. Current protocols in immunology 2005, [Chapter 12], Unit 12.12. J.E. Coligan (Ed.).
70. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T-cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004, 22:745-763.
71. Sallusto F., Lenig D., Förster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401:708-712.
72. Lanzavecchia A., Sallusto F. Understanding the generation and function of memory T-cell subsets. Curr Opin Immunol 2005, 17:326-332.
73. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8:247-258.
74. Appay V., Almeida J.R., Sauce D., Autran B., Papagno L. Accelerated immune senescence and HIV-1 infection. Exp Gerontol 2007, 42:432-437.
75. + T-cells in HIV infection. JImmunol 2009, 183:1120-1132.
76. Wherry E.J., Blattman J.N., Murali-Krishna K., van der Most R., Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. JVirol 2003, 77(8):4911-4927.
77. + T-cell exhaustion during chronic viral infection. Immunity 2007, 27(4):670-684.
78. + T-cells in mice. Med Hypotheses Jul, 2013, 83(1):69-73.
79. Ishida Y., Agata Y., Shibahara K., Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992, 11:3887-3895.
80. Kaufmann D.E., Walker B.D. Programmed death-1 as a factor in immune exhaustion and activation in HIV infection. Curr Opin HIV AIDS 2008, 3:362-367.
81. + T-cells in mice. JClin Invest Jun 3, 2013, 123(6):2629-2642.
82. Monney L., Sabatos C.A., Gaglia J.L., Ryu A., Waldner H., Chernova T., et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002, 415:536-541.
83. Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J., et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005, 6:1245-1252.
84. Hafler D.A., Kuchroo V. TIMs: central regulators of immune responses. JExp Med 2008, 205:2699-2701.
85. + T-cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009, 10:29-37.
86. Richter K., Agnellini P., Oxenius A. On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection. Int Immunol 2010, 22:13-23.
87. Romagnani S. Th1 and Th2 in human diseases. Clin Immunol Immunopathol 1996, 80:225-235.
88. Larsson M., Shanker E.M., Chek F., Saeidi A., Ellegard R., Barathan M., et al. Molecular signature of T-cell inhibition in HIV-1 infection. Retrovirology May 20, 2013, 10:31.
89. Pawelec G., Derhovanessian E., Larbi A. Immunosenescence and cancer. Crit Rev Oncol Hematol 2010, 75:165-172.
90. Ngrádi J., Kövesdi V. Factors that may impact on immunosenescence: an appraisal. Immun Ageing 2010, 7.
91. +CD28 - cell population in the blood and lung of HIV-positive patients. JAcquir Immune Defic Syndr 1993, 6:1194-1204.
92. + cell subset in HIV disease implicate replicative senescence in HIV pathogenesis. AIDS 1996, 10(8):F17-F22.
93. + lymphocyte apoptosis, chronic disease, and immune regulation. Front Biosci 2009, 14:3771-3781.
94. Sacre K., Carcelain G., Cassoux N., Fillet A.M., Costagliola D., Vittecoq D., et al. Repertoire, diversity, and differentiation of specific CD8 T-cells are associated with immune protection against human cytomegalovirus disease. JExp Med 2005, 201:1999-2010.
95. +) T-cell response. JImmunol 2002, 168:5455-5464.
96. +) T-cells from a memory to memory/effector phenotype. JImmunol 2002, 168:5538-5550.
97. + T lymphocytes in human immunodeficiency virus-infected patients. Immunology 2007, 121:405-415.
98. + T-cells and their association with HIV-1-induced T-cell dysfunction. JImmunol 2005, 175:8415-8423.
99. Chattopadhyay P.K., Betts M.R., Price D.A., Gostick E., Horton H., Roederer M., et al. The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. JLeukoc Biol 2008.
100. Kaufmann D.E., Walker B.D. PD-1 and CTLA-4 inhibitory co signaling pathways in HIV infection and the potential for therapeutic intervention. JImmunol 2009, 182:5891-5897.
101. Day C.L., Kaufmann, Kiepiela P., Brown J.A., Moodley E.S., Reddy S., et al. PD-1 expression on HIV-specific T-cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
102. Holm M., Pettersen F.O., Kvale D. PD-1 predicts CD4 loss rate in chronic HIV-1 infection better than HIV RNA and CD38 but not in cryopreserved samples. Curr HIV Res 2008, 6:49-58.
103. Velu V., Kannanganat S., Ibegbu C., Chennareddi L., Villinger F., Freeman G.J., et al. Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T-cells during chronic infection but not after vaccination. JVirol 2007, 81:5819-5828.
104. + T-cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007, 8:1246-1254.
105. Henson S.M., Akbar A.N. KLRG1- more than a marker for T-cell senescence. Age 2009, 31:285-291.
106. Wang H., Kotler D.P. HIV enteropathy and aging: gastrointestinal immunity, mucosal epithelial barrier and microbial translocation. Curr Opin HIV AIDS 2014, 9(4):309-316.
107. Benedict C.A., Norris P.S., Ware C.F. To kill or be killed: viral evasion of apoptosis. Nat Immunol 2002, 3:1013-1018.
108. Poonia B., Pauza C.D., Salvato M.S. Role of the Fas/FasL pathway in HIV or SIV disease. Retrovirology 2009, 6:91.
109. + T-cells in multiple tissues during acute SIV infection. Nature 2005, 434:1093-1197.
110. + T-cells. Nature 2005, 434:1148-1152.
111. + T-cell induction in neutralizing antibody-triggered control of simian immunodeficiency virus infection. JVirol 2009, 83:5514-5524.
112. + T-cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. JImmunol 2004, 173:2410-2418.
113. Trapani J.A., Smyth M.J. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol 2002, 2:735-747.
114. Yang O.O. Aiming for successful vaccine-induced HIV-1-specific cytotoxic T lymphocytes. AIDS 2008, 22:325-331.
115. Appay V., Nixon D.F., Donahoe S.M., Gillespie G.M.A., Dong T., King A., et al. HIV-specific CD8 (+) T-cells produce antiviral cytokines but are impaired in cytolytic function. JExp Med 2000, 192:63-75.
116. Chattopadhyay P.K., Roederer M. Good cell, bad cell: flow cytometry reveals T-cell subsets important in HIV disease. Cytometry 2011, 1.
117. Andrew J.M., Persephone B., Georgia D., Goonetilleke N., Haynes B.F. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010, 10:11-23.
118. Gershon R.K., Kondo K. Infectious immunological tolerance. Immunology 1971, 21:903-914.
119. + T-cell clusters. Front Immunol May 8, 2014, 5:199.
120. + T-cells inhibit both the induction and effector function of autoreactive T-cells and represent a unique lineage of immunoregulatory cells. JImmunol 1998, 160:1212-1218.
121. Khattri R., Kasprowicz D., Cox T., Mortrud M., Appleby M.W., Brunkow M.E., et al. The amount of scurfin protein determines peripheral T-cell number and responsiveness. JImmunol 2001, 167:6312-6320.
122. +) regulatory T-cells. JInfect Dis 2009, 199:1318-1322.
123. +/hi) CD127 (lo) phenotype does not accurately identify regulatory T-cells in all populations of HIV- infected persons. JInfect Dis 2010, 201:331-335.
124. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T-cells. JExp Med 2006, 203:1693-1700.
125. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007, 110:1225-1232.
126. Nocentini G., Giunchi L., Ronchetti S., Krausz L.T., Bartoli A., Moraca R., et al. Anew member of the tumor necrosis factor/nerve growth factor receptor family inhibits T-cell receptor-induced apoptosis. Proc Natl Acad Sci U S A 1997, 94:6216-6221.
127. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173.
128. Mangan P.R., Harrington L.E., O'Quinn D.B., He;ms W.S., Bullard D.C., Elson C.O., et al. Transforming growth factor-beta induces development of the T (H) 17 lineage. Nature 2006, 441:231-234.
129. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T-cells. Immunity 2006, 24:179.
130. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T-cells. Nature 2006, 441:235-238.
131. Mucida D., Park Y., Kim G., Turovskaya O., Scott I., Kronenberg M., et al. Reciprocal TH17 and regulatory T-cell differentiation mediated by retinoic acid. Science 2007, 317:256-260.
132. Zhou L., Lopes J.E., Chong M.M., Ivanov I.I., Min R., Victora G.D., et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008, 453:236-240.
133. Quintana F.J., Basso A.S., Iglesias A.H., Korn T., Mauricio F.F., Bettelli E., et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008, 453:65-71.
134. Veldhoen M., Hirota K., Christensen J., O'Garra A., Stockinger B. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T-cells. JExp Med 2009, 206:43-49.
135. + effector T-cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
136. +) memory T-cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol 2009, 2:439-449.
137. + regulatory T-cells. JImmunol 2008, 180:122-129.
138. Dyer J.R., Kazembe P., Vernazza P.L., Gilliam B.L., Maida M., Zimba D., et al. High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. JInfect Dis 2008, 177:1742-1746.